Protekt Therapeutics

Company Overview

Snapshot

Founded in December 2014 by Prof. Kobi Rosenblum, Protekt Therapeutics operates with 1–10 employees. The company has raised a total of $13.85 million across 4 funding rounds from 10 investors. In November 2019, Protekt Therapeutics secured funding from investors including OrbiMed.

Business overview

Protekt Therapeutics is a biopharmaceutical company focused on identifying and developing potent and selective oral PKR inhibitors (PKRi) to treat cognitive disorders such as Alzheimer's disease and mild cognitive impairment. The company's core technology targets PKR, a stress and proapoptotic kinase that plays a role in inhibiting protein synthesis and impairing memory consolidation. By modulating multiple key processes involved in neurodegenerative diseases like Alzheimer's, Protekt Therapeutics aims to offer a novel disease-modifying mechanism. The company operates within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals and Drugs Discovery & Development, serving patients in markets across Asia, the United States, and Europe.

Strategic signal

In November 2019, Protekt Therapeutics raised $3.6 million, a significant validation of its approach to developing PKR inhibitors for neurodegenerative diseases. This funding, involving investors like OrbiMed and RMGP Biopharma Investment Fund, signals continued investor confidence in the company's research and development efforts, particularly its focus on a novel mechanism for treating complex conditions like Alzheimer's. For investors and innovation teams, this indicates ongoing progress and potential in the biopharmaceutical space for cognitive disorder treatments.

Company Intelligence Q&A

What is Protekt Therapeutics' primary focus?

Protekt Therapeutics focuses on developing a potent and selective oral PKR inhibitor (PKRi) to treat cognitive disorders such as Alzheimer's disease and mild cognitive impairment.

When was Protekt Therapeutics founded?

Protekt Therapeutics was founded in December 2014.

Which incubator supported Protekt Therapeutics' establishment?

Protekt Therapeutics was established in the FutuRx Incubator in December 2015, based on technology from Prof. Kobi Rosenblum's lab at Haifa University.

What was a key funding event for Protekt Therapeutics?

In November 2019, Protekt Therapeutics raised $3.6 million from investors including OrbiMed.

What is the total capital raised by Protekt Therapeutics?

Protekt Therapeutics has raised a total of $13.85 million across four funding rounds.